CAMBRIDGE, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported financial results for the second quarter ended June 30, 2017, and provided an update on recent developments.
“The first half of the year was highly productive for our Company, marked by significant progress across multiple clinical studies with our lead product candidate, and operationally, with the completion of a successful IPO,” said Joseph A. Yanchik III, President and CEO.
